Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor A (VEGF-A) and is used to treat the below conditions. Its use is typically in combination with other chemotherapy agents.

**FDA-approved Indications**

- Cervical cancer: Bevacizumab has approval for treating recurrent, persistent, or metastatic cervical cancer in combination with paclitaxel and either cisplatin or topotecan.

- Metastatic colorectal cancer: Bevacizumab is a first-line or second-line therapy for metastatic colorectal cancer combined with fluorouracil (FU)-based chemotherapy regimens.

- Glioblastoma: Bevacizumab has approval as a single agent in patients with progressive glioblastoma following previous therapy.

- Non-squamous non-small cell lung cancer (NSCLC): Bevacizumab is a first-line treatment combination with carboplatin and paclitaxel for recurrent, locally advanced, unresectable, or metastatic non-squamous non-small cell lung cancer.

- Ovarian, fallopian tube, or primary peritoneal cancer: Bevacizumab has approved the treatment of platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with a carboplatin chemotherapy regimen or the treatment of platinum-resistant disease in combination with paclitaxel, doxorubicin, or topotecan.

- Metastatic renal cell carcinoma: Bevacizumab has received approval to treat metastatic renal cell carcinoma in combination with interferon alfa.

- Hepatocellular carcinoma (HCC): Bevacizumab, in combination with atezolizumab, is indicated for treating unresectable metastatic hepatocellular carcinoma patients.

**Off-label Indications**

- Metastatic breast cancer

- Endometrial cancer

- Angiosarcoma

- Gliomas

- Malignant pleural mesothelioma

- Medulloblastoma (pediatric)

- Diabetic macular edema

- Age-related macular degeneration

- Hemangiopericytoma and malignant solitary fibrous tumor

- Hereditary hemorrhagic telangiectasia